Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985530 · ClinicalTrials.gov registry record · Phase 1
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00985530 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 4 participants.
The verdict
NCT00985530, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy. This research study involves testing an investigational drug called Tamibarotene in combination with standard treatment for relapsed APL called arsenic trioxide. Tamibarotene has been approved in Japan to treat patients with relapsed APL since April 2005. Tamibarotene is in the same family of drugs as all-trans retinoic acid (ATRA), a medication that subjects received previously in their treatment. ATRA and tamibarotene both cause the APL cells to differentiate (or become) normal non-leukemia cells. Laboratory studies of tamibarotene have shown to be effective in APL. The purpose of this study is to determine if tamibarotene in combination with arsenic trioxide is safe and effective.
Interventions
- DRUG Tamibarotene
- DRUG Arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985530
The ClinicalTrials.gov registry entry for NCT00985530 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamibarotene is the first listed.
NCT00985530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00985530 about?
NCT00985530 is a clinical study titled "Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia". Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy. This research study involves testing an investigational drug called Tamibarotene in combination with standard treatment for relapsed APL called arsenic tr...
What is the current status of trial NCT00985530?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-10. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00985530?
The interventions under investigation include: Tamibarotene (DRUG), Arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00985530?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.